Shares of Baudax Bio BXRX fell 3.1% in pre-market trading after the company reported Q4 results.
Quarterly Results
Earnings per share increased 88.46% year over year to ($0.09), which beat the estimate of ($0.61).
Revenue of $76,000 up by 0.00% from the same period last year, which missed the estimate of $1,630,000.
Looking Ahead
Baudax Bio hasn't issued any earnings guidance for the time being.
Baudax Bio hasn't issued any revenue guidance for the time being.
How To Listen To The Conference Call
Date: Feb 16, 2021
Time: 08:00 AM
ET Webcast URL: https://edge.media-server.com/mmc/p/iyn57hn2
Recent Stock Performance
Company's 52-week high was at $10.14
52-week low: $0.97
Price action over last quarter: Up 85.41%
Company Description
Baudax Bio Inc is a Pharmaceutical company. The company develops and commercialize products for hospital and related acute care settings. Its products are in pipeline which includes two novel neuromuscular blocking agents, or NMBAs, and a related proprietary chemical reversal agent and Dex-IN.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
